Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy

Hsu Heng Yen, Chia Wei Yang, Wei Wen Su, Maw Soan Soon, Shun Sheng Wu, Hwai Jeng Lin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: High dose intravenous proton pump inhibitor after endoscopic therapy for peptic ulcer bleeding has been recommended as adjuvant therapy. Whether oral proton pump inhibitor can replace intravenous proton pump inhibitor in this setting is unknown. This study aims to compare the clinical efficacy of oral and intravenous proton pump inhibitor after endoscopic therapy.Methods: Patients with high-risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group. Primary outcome of the study was re-bleeding rate within 14 days. Secondary outcome included hospital stay, volume of blood transfusion, surgical intervention and mortality within 1 month.Results: From April 2010 to Feb 2011, 100 patients were enrolled in this study. The re-bleeding rates were 4% (2/50) in the intravenous group and 4% (2/50) in the oral group. There was no difference between the two groups with regards to the hospital stay, volume of blood transfusion, surgery or mortality rate. The mean duration of hospital stay was 1.8 days in the oral lansoprazole group and 3.9 days in the intravenous esomeprazole group (p > 0.01).Conclusion: Patients receiving oral proton pump inhibitor have a shorter hospital stay. There is no evidence of a difference in clinical outcomes between oral and intravenous PPI treatment. However, the study was not powered to prove equivalence or non-inferiority. Future studies are still needed.Trial registration: NCT01123031.

Original languageEnglish
Article number66
JournalBMC Gastroenterology
Volume12
DOIs
Publication statusPublished - Jun 8 2012

Fingerprint

Proton Pump Inhibitors
Peptic Ulcer
Hemorrhage
Length of Stay
Esomeprazole
Lansoprazole
Blood Transfusion
Therapeutics
Mortality
Outcome Assessment (Health Care)

Keywords

  • Endoscopic therapy
  • Hemostasis
  • High risk
  • Peptic ulcer
  • Peptic ulcer bleeding
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. / Yen, Hsu Heng; Yang, Chia Wei; Su, Wei Wen; Soon, Maw Soan; Wu, Shun Sheng; Lin, Hwai Jeng.

In: BMC Gastroenterology, Vol. 12, 66, 08.06.2012.

Research output: Contribution to journalArticle

@article{8140c902cfb44864a6947cecf8137c8b,
title = "Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy",
abstract = "Background: High dose intravenous proton pump inhibitor after endoscopic therapy for peptic ulcer bleeding has been recommended as adjuvant therapy. Whether oral proton pump inhibitor can replace intravenous proton pump inhibitor in this setting is unknown. This study aims to compare the clinical efficacy of oral and intravenous proton pump inhibitor after endoscopic therapy.Methods: Patients with high-risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group. Primary outcome of the study was re-bleeding rate within 14 days. Secondary outcome included hospital stay, volume of blood transfusion, surgical intervention and mortality within 1 month.Results: From April 2010 to Feb 2011, 100 patients were enrolled in this study. The re-bleeding rates were 4{\%} (2/50) in the intravenous group and 4{\%} (2/50) in the oral group. There was no difference between the two groups with regards to the hospital stay, volume of blood transfusion, surgery or mortality rate. The mean duration of hospital stay was 1.8 days in the oral lansoprazole group and 3.9 days in the intravenous esomeprazole group (p > 0.01).Conclusion: Patients receiving oral proton pump inhibitor have a shorter hospital stay. There is no evidence of a difference in clinical outcomes between oral and intravenous PPI treatment. However, the study was not powered to prove equivalence or non-inferiority. Future studies are still needed.Trial registration: NCT01123031.",
keywords = "Endoscopic therapy, Hemostasis, High risk, Peptic ulcer, Peptic ulcer bleeding, Proton pump inhibitor",
author = "Yen, {Hsu Heng} and Yang, {Chia Wei} and Su, {Wei Wen} and Soon, {Maw Soan} and Wu, {Shun Sheng} and Lin, {Hwai Jeng}",
year = "2012",
month = "6",
day = "8",
doi = "10.1186/1471-230X-12-66",
language = "English",
volume = "12",
journal = "BMC Gastroenterology",
issn = "1471-230X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy

AU - Yen, Hsu Heng

AU - Yang, Chia Wei

AU - Su, Wei Wen

AU - Soon, Maw Soan

AU - Wu, Shun Sheng

AU - Lin, Hwai Jeng

PY - 2012/6/8

Y1 - 2012/6/8

N2 - Background: High dose intravenous proton pump inhibitor after endoscopic therapy for peptic ulcer bleeding has been recommended as adjuvant therapy. Whether oral proton pump inhibitor can replace intravenous proton pump inhibitor in this setting is unknown. This study aims to compare the clinical efficacy of oral and intravenous proton pump inhibitor after endoscopic therapy.Methods: Patients with high-risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group. Primary outcome of the study was re-bleeding rate within 14 days. Secondary outcome included hospital stay, volume of blood transfusion, surgical intervention and mortality within 1 month.Results: From April 2010 to Feb 2011, 100 patients were enrolled in this study. The re-bleeding rates were 4% (2/50) in the intravenous group and 4% (2/50) in the oral group. There was no difference between the two groups with regards to the hospital stay, volume of blood transfusion, surgery or mortality rate. The mean duration of hospital stay was 1.8 days in the oral lansoprazole group and 3.9 days in the intravenous esomeprazole group (p > 0.01).Conclusion: Patients receiving oral proton pump inhibitor have a shorter hospital stay. There is no evidence of a difference in clinical outcomes between oral and intravenous PPI treatment. However, the study was not powered to prove equivalence or non-inferiority. Future studies are still needed.Trial registration: NCT01123031.

AB - Background: High dose intravenous proton pump inhibitor after endoscopic therapy for peptic ulcer bleeding has been recommended as adjuvant therapy. Whether oral proton pump inhibitor can replace intravenous proton pump inhibitor in this setting is unknown. This study aims to compare the clinical efficacy of oral and intravenous proton pump inhibitor after endoscopic therapy.Methods: Patients with high-risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group. Primary outcome of the study was re-bleeding rate within 14 days. Secondary outcome included hospital stay, volume of blood transfusion, surgical intervention and mortality within 1 month.Results: From April 2010 to Feb 2011, 100 patients were enrolled in this study. The re-bleeding rates were 4% (2/50) in the intravenous group and 4% (2/50) in the oral group. There was no difference between the two groups with regards to the hospital stay, volume of blood transfusion, surgery or mortality rate. The mean duration of hospital stay was 1.8 days in the oral lansoprazole group and 3.9 days in the intravenous esomeprazole group (p > 0.01).Conclusion: Patients receiving oral proton pump inhibitor have a shorter hospital stay. There is no evidence of a difference in clinical outcomes between oral and intravenous PPI treatment. However, the study was not powered to prove equivalence or non-inferiority. Future studies are still needed.Trial registration: NCT01123031.

KW - Endoscopic therapy

KW - Hemostasis

KW - High risk

KW - Peptic ulcer

KW - Peptic ulcer bleeding

KW - Proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84861946727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861946727&partnerID=8YFLogxK

U2 - 10.1186/1471-230X-12-66

DO - 10.1186/1471-230X-12-66

M3 - Article

C2 - 22681960

AN - SCOPUS:84861946727

VL - 12

JO - BMC Gastroenterology

JF - BMC Gastroenterology

SN - 1471-230X

M1 - 66

ER -